281 related articles for article (PubMed ID: 17419945)
1. c-MYC impairs immunogenicity of human B cells.
Schlee M; Schuhmacher M; Hölzel M; Laux G; Bornkamm GW
Adv Cancer Res; 2007; 97():167-88. PubMed ID: 17419945
[TBL] [Abstract][Full Text] [Related]
2. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.
Staege MS; Lee SP; Frisan T; Mautner J; Scholz S; Pajic A; Rickinson AB; Masucci MG; Polack A; Bornkamm GW
Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4550-5. PubMed ID: 11917131
[TBL] [Abstract][Full Text] [Related]
3. Forward and reverse changes in Ig/myc translocation carrying tumors.
Klein G
Princess Takamatsu Symp; 1989; 20():135-42. PubMed ID: 2562178
[TBL] [Abstract][Full Text] [Related]
4. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
5. Suppression of the malignant phenotype in somatic cell hybrids between Burkitt's lymphoma cells and Epstein-Barr virus-immortalized lymphoblastoid cells despite deregulated c-myc expression.
Wolf J; Pawlita M; Bullerdiek J; zur Hausen H
Cancer Res; 1990 May; 50(10):3095-100. PubMed ID: 2159373
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
Jochner N; Eick D; Zimber-Strobl U; Pawlita M; Bornkamm GW; Kempkes B
EMBO J; 1996 Jan; 15(2):375-82. PubMed ID: 8617212
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus and Burkitt's lymphoma.
Magrath I; Jain V; Bhatia K
Semin Cancer Biol; 1992 Oct; 3(5):285-95. PubMed ID: 1335792
[TBL] [Abstract][Full Text] [Related]
8. C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma.
Schlee M; Hölzel M; Bernard S; Mailhammer R; Schuhmacher M; Reschke J; Eick D; Marinkovic D; Wirth T; Rosenwald A; Staudt LM; Eilers M; Baran-Marszak F; Fagard R; Feuillard J; Laux G; Bornkamm GW
Int J Cancer; 2007 Apr; 120(7):1387-95. PubMed ID: 17211884
[TBL] [Abstract][Full Text] [Related]
9. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
Arasi VE; Lieberman R; Sandlund J; Kiwanuka J; Novikovs L; Kirsch I; Hollis G; Magrath IT
Cancer Res; 1989 Jun; 49(12):3235-41. PubMed ID: 2497974
[TBL] [Abstract][Full Text] [Related]
10. EBV-B cell interactions: immortalization, rescue from apoptosis, tumorigenicity (a short review).
Klein G
Acta Microbiol Immunol Hung; 1996; 43(2-3):97-105. PubMed ID: 8876725
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2.
Kelly G; Bell A; Rickinson A
Nat Med; 2002 Oct; 8(10):1098-104. PubMed ID: 12219084
[TBL] [Abstract][Full Text] [Related]
12. The in vivo binding site for oncoprotein c-Myc in the promoter for Epstein-Barr virus (EBV) encoding RNA (EBER) 1 suggests a specific role for EBV in lymphomagenesis.
Niller HH; Salamon D; Ilg K; Koroknai A; Banati F; Bauml G; Rucker O; Schwarzmann F; Wolf H; Minarovits J
Med Sci Monit; 2003 Jan; 9(1):HY1-9. PubMed ID: 12552250
[TBL] [Abstract][Full Text] [Related]
13. The etiology of Burkitt's lymphoma and the history of the shaken dogmas.
de Thé G
Blood Cells; 1993; 19(3):667-73; discussion 674-5. PubMed ID: 8018947
[TBL] [Abstract][Full Text] [Related]
14. Stable nontumorigenic phenotype of somatic cell hybrids between malignant Burkitt's lymphoma cells and autologous EBV-immortalized B cells despite induction of chromosomal breakage and loss.
Jox A; Taquia E; Vockerodt M; Draube A; Pawlita M; Möller P; Bullerdiek J; Diehl V; Wolf J
Cancer Res; 1998 Nov; 58(21):4930-9. PubMed ID: 9810002
[TBL] [Abstract][Full Text] [Related]
15. The Epstein-Barr virus BRLF1 gene product transactivates the murine and human c-myc promoters.
Gutsch DE; Marcu KB; Kenney SC
Cell Mol Biol (Noisy-le-grand); 1994 Sep; 40(6):747-60. PubMed ID: 7812182
[TBL] [Abstract][Full Text] [Related]
16. Cell phenotype dependent expression of MHC class I antigens in Burkitt's lymphoma cell lines.
Masucci MG; Klein E
Semin Cancer Biol; 1991 Feb; 2(1):63-71. PubMed ID: 1655115
[TBL] [Abstract][Full Text] [Related]
17. Immunological aspects of B-cell derived tumors in humans and rodents.
Klein G
Princess Takamatsu Symp; 1988; 19():3-13. PubMed ID: 2855874
[TBL] [Abstract][Full Text] [Related]
18. Conditioned tumorigenicity of activated oncogenes.
Klein G; Klein E
Cancer Res; 1986 Jul; 46(7):3211-24. PubMed ID: 3011242
[TBL] [Abstract][Full Text] [Related]
19. Constitutive activation of oncogenes by chromosomal translocations in B-cell derived tumors.
Klein G
AIDS Res; 1986 Dec; 2 Suppl 1():S167-76. PubMed ID: 3030345
[TBL] [Abstract][Full Text] [Related]
20. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift.
Strobl LJ; Kohlhuber F; Mautner J; Polack A; Eick D
Oncogene; 1993 Jun; 8(6):1437-47. PubMed ID: 8502472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
